Version 1
: Received: 16 December 2022 / Approved: 21 December 2022 / Online: 21 December 2022 (04:56:44 CET)
How to cite:
Aubry, M.; Maset, N.; Chapman, L.; Simon, A.; Olivier, S.; Bos, R.; Chung, K.; Teiti, I.; Kucharski, A.; Mallet, H.; Cao-Lormeau, V. Seroprevalence of SARS-CoV-2 Antibodies in French Polynesia and Perspective for Vaccine Strategies. Preprints2022, 2022120386. https://doi.org/10.20944/preprints202212.0386.v1
Aubry, M.; Maset, N.; Chapman, L.; Simon, A.; Olivier, S.; Bos, R.; Chung, K.; Teiti, I.; Kucharski, A.; Mallet, H.; Cao-Lormeau, V. Seroprevalence of SARS-CoV-2 Antibodies in French Polynesia and Perspective for Vaccine Strategies. Preprints 2022, 2022120386. https://doi.org/10.20944/preprints202212.0386.v1
Aubry, M.; Maset, N.; Chapman, L.; Simon, A.; Olivier, S.; Bos, R.; Chung, K.; Teiti, I.; Kucharski, A.; Mallet, H.; Cao-Lormeau, V. Seroprevalence of SARS-CoV-2 Antibodies in French Polynesia and Perspective for Vaccine Strategies. Preprints2022, 2022120386. https://doi.org/10.20944/preprints202212.0386.v1
APA Style
Aubry, M., Maset, N., Chapman, L., Simon, A., Olivier, S., Bos, R., Chung, K., Teiti, I., Kucharski, A., Mallet, H., & Cao-Lormeau, V. (2022). Seroprevalence of SARS-CoV-2 Antibodies in French Polynesia and Perspective for Vaccine Strategies. Preprints. https://doi.org/10.20944/preprints202212.0386.v1
Chicago/Turabian Style
Aubry, M., Henri-Pierre Mallet and Van-Mai Cao-Lormeau. 2022 "Seroprevalence of SARS-CoV-2 Antibodies in French Polynesia and Perspective for Vaccine Strategies" Preprints. https://doi.org/10.20944/preprints202212.0386.v1
Abstract
In French Polynesia, Wuhan, Delta and Omicron SARS-CoV-2 variants-of-concern (VOCs) caused epidemics withvariable severities. We assessed the prevalence and titers of anti-SARS-CoV-2 antibodies related to natural infection and/or vaccination, from a representative sample (N=673) of the adult population of Tahiti recruited during November-December 2021 (after the Delta outbreak and just before the Omicron epidemic). Of the 673 participants tested, 644 (95.7%) had detectable antibodies against SARS-CoV-2-S and/or -N proteins resulting from natural infection and/or vaccination, and 388 (57.7%) were positive only for the detection of anti-N antibodies indicating natural infection. SARS-CoV-2 seroprevalence extrapolated to the adult population of Tahiti was estimated at 95.9%.Concentrations of anti-SARS-CoV-2-S antibodies significantly increased with age, number of self-reported SARS-CoV-2 infections (0 or ≥1), and number of COVID-19 vaccine doses (0, 1, 2, or 3) received by the participants. Elderly people, who are at higher risk of severe outcomes, had received more vaccine doses than younger individuals both in our sample and in the general population. The high level of antibody responses related to past infections and vaccination, especially booster doses, has likely contributed to reducing the severity of the Omicron outbreak in French Polynesia.
Keywords
SARS-CoV-2; COVID-19; seroprevalence; antibodies; vaccine; natural infection; French Polynesia
Subject
Biology and Life Sciences, Virology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
